• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

Novo Nordisk cuts 9K jobs to save $1.26B amid Wegovy growth, Eli Lilly rivalry

by September 10, 2025
by September 10, 2025

Novo Nordisk, the Danish pharmaceutical giant behind the obesity drug Wegovy, said on Wednesday it will cut about 9,000 jobs globally in a major restructuring effort, aiming to save 8 billion Danish crowns ($1.26 billion) annually.

The move underscores the growing pressure the company faces from its US rival Eli Lilly as the weight-loss drug market becomes increasingly crowded and competitive.

The company, which currently employs 78,400 people worldwide, said approximately 5,000 of the planned job reductions will be in Denmark.

“Our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven. Our company must evolve as well,” newly appointed CEO Mike Doustdar said in the statement.

“This means instilling an increased performance-based culture, deploying our resources ever more effectively, and prioritising investment where it will have the most impact – behind our leading therapy areas,” he added.

Costs and financial impact

Novo said restructuring costs of about 9 billion Danish crowns will be incurred in the third quarter of 2025. However, it also expects 1 billion crowns of savings in the fourth quarter, it said.

It also warned that the overhaul would carry a one-off negative impact of around six percentage points on its full-year operating profit growth at constant exchange rates next year.

Novo said its operating profit growth this year is now expected at between 4% and 10%, down from between 10% and 16% seen last month, changing solely due to the restructuring costs.

It also projected depreciation, amortisation, and impairment losses of 21 billion crowns, higher than its earlier estimate of 17 billion crowns.

Growth slowdown weighs on shares

Novo Nordisk, once Europe’s most valuable listed company with a market value of $650 billion in 2023, has seen its growth slow significantly.

Last month, the company warned that revenues would fall well short of earlier forecasts, citing competition from Eli Lilly’s Mounjaro and Zepbound, as well as the rise of cheaper copycat versions of its drugs.

The company’s Copenhagen-listed shares are down nearly 47% so far this year, reflecting investor concerns over the competitive landscape and Novo’s ability to maintain its dominance in the GLP-1 drug segment.

Doustdar’s leadership began on August 7, 2025, following the exit of Lars Fruergaard Jørgensen.

However, the timing of his appointment coincided with a sharp cut to Novo’s sales forecast which has also sent investor confidence tumbling.

Adding to the pressure, Denmark’s government recently lowered its 2025 economic growth forecast to 1.4% from 3%, citing weaker prospects for Novo Nordisk and new US tariffs on Danish exports.

For a company that once outpaced the size of Denmark’s economy, Novo’s latest restructuring marks a critical juncture in its bid to defend market share and restore growth momentum.

The post Novo Nordisk cuts 9K jobs to save $1.26B amid Wegovy growth, Eli Lilly rivalry appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Ocado share price analysis: is this fallen angel a buy?
next post
End of an era? Zara owner Inditex Q2 sales disappoint due to cautious consumers

Related Posts

Europe bulletin: Zelensky calls for more weapons, Russia...

October 25, 2025

Nvidia stock edges higher amid semiconductor sector rally...

October 25, 2025

AMD stock climbs 7%, breaching $400B market cap...

October 25, 2025

US digest: Jeffries endorses Mamdani, Ford’s stock surge,...

October 25, 2025

Trump seeks Asia mineral deals to ramp up...

October 25, 2025

Lucy Powell elected deputy leader of the UK’s...

October 25, 2025

Disney warns YouTube TV subscribers of potential blackout...

October 24, 2025

Top catalysts for the CAC 40 index next...

October 24, 2025

European stocks open higher, buoyed by a wave...

October 24, 2025

NatWest share price forecast as its earnings jump:...

October 24, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • Europe bulletin: Zelensky calls for more weapons, Russia warns against EU sanctions

    October 25, 2025
  • Nvidia stock edges higher amid semiconductor sector rally and AI boom

    October 25, 2025
  • AMD stock climbs 7%, breaching $400B market cap amid chip sector rally

    October 25, 2025
  • US digest: Jeffries endorses Mamdani, Ford’s stock surge, US sanctions Colombian president

    October 25, 2025
  • Trump seeks Asia mineral deals to ramp up pressure on China’s Xi: report

    October 25, 2025
  • Lucy Powell elected deputy leader of the UK’s Labour Party

    October 25, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Pop Mart reports 188% profit surge, plans aggressive global expansion

    March 26, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 5

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 6

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 7

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025

Categories

  • Economy (3,000)
  • Editor's Pick (295)
  • Investing (185)
  • Stock (2,048)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Top Nifty 50 Index gainers and losers...

August 25, 2025

Morgan Stanley foresees volatility for Match, Bumble...

July 29, 2025

NVDY, NVDL ETFs analysis ahead of the...

February 24, 2025